Attached files
| file | filename |
|---|---|
| 8-K - BODY OF FORM 8-K - Teligent, Inc. | d903043_igi8k.htm |
Exhibit 99.1
News From:
![[ex99_903043002.gif]](ex99_903043002.gif)
Release Date: April 29, 2014
Contact:
Jenniffer Collins
IGI Laboratories, Inc.
(856) 697-1441
www.igilabs.com
IGI LABORATORIES ANNOUNCES FIRST QUARTER 2014 RESULTS
BUENA, NJ - (PR NEWSWIRE) – IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the first quarter ended March 31, 2014.
First Quarter 2014 Highlights
| • | Total revenues of $6.9 million in the first quarter of 2014, an increase of 86% over the same quarter in |
| • | Total net revenues generated from the sale of IGI label generic topical pharmaceutical products for the |
| • | Gross profit for the period ended March 31, 2014 grew to 42% as compared to 30% in the same period |
| • | IGI filed its fourteenth Abbreviated Drug Application, or ANDA, with the U.S. Food and Drug |
| • | IGI received its first approval from the FDA for an ANDA for lidocaine hydrochloride USP 4% topical |
| • | Net income was $0.2 million in the first quarter of 2014, compared to a net loss of $0.3 million in the |
IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “The first quarter represents a strong start to our year of transformation. We received our first ANDA approval for lidocaine hydrochloride USP 4% topical solution in March. This was a huge milestone for IGI, and validated our organic research and development expertise. On the financial front, we increased total revenue 86 percent over the same quarter last year, and improved margins to end the first quarter of 2014 with a gross margin of 42%, compared to 30% one year ago. As promised, we maintained profitability in the first quarter of 2014, even though we significantly increased our expenses related to research and development. We continue to expect to file at least ten ANDAs in 2014, and we have accelerated our R&D efforts in order to meet our commitments.” Mr. Grenfell-Gardner continued, “We continue to expect revenue to increase between 40% and 45% over 2013. We are committed to sustain profitability in 2014, even though we plan to at least double our spending in research and development in 2014 over 2013.”
The Company will hold a conference call today at 4:30 pm ET to discuss first quarter 2014 results.
The Company invites you to listen to the call by dialing 1-866-515-2913. International participants should call 1-617-399-5127. The passcode for the conference call is 66700649.
This call is being webcast by NASDAQ OMX and can be accessed at IGI's website at www.igilabs.com.
The webcast is also being distributed through third party distribution channels, including the StreetEvents Network operated by Thompson Reuters (Markets) LLC and its affiliates.
1
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the three months ended March 31, 2014 and 2013
(in thousands, except shares and per share information)
(Unaudited)
| 2014 |
| 2013 | ||
Revenues: |
|
|
|
|
|
Product sales, net | $ | 6,383 |
| $ | 3,467 |
Research and development income |
| 313 |
|
| 159 |
Licensing, royalty and other revenue |
| 157 |
|
| 57 |
Total revenues |
| 6,853 |
|
| 3,683 |
|
|
|
|
|
|
Costs and Expenses: |
|
|
|
|
|
Cost of sales |
| 3,987 |
|
| 2,575 |
Selling, general and administrative expenses |
| 1,282 |
|
| 679 |
Product development and research expenses |
| 1,365 |
|
| 658 |
Total costs and expenses |
| 6,634 |
|
| 3,912 |
Operating income (loss) |
| 219 |
|
| (229) |
Interest expense and other, net |
| (52) |
|
| (28) |
|
|
|
|
|
|
Net Income (Loss) | $ | 167 |
| $ | (257) |
|
|
|
|
|
|
Basic income (loss) per share | $ | 0.00 |
| $ | (0.01) |
Diluted income (loss) per share | $ | 0.00 |
| $ | (0.01) |
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
Basic | 46,826,733 |
| 42,933,146 | ||
Diluted | 48,529,603 |
| 42,933,146 | ||
2
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share information)
(Unaudited)
| March 31, |
| December 31, | ||
ASSETS |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents | $ | 2,414 |
| $ | 2,101 |
Accounts receivable, net |
| 4,120 |
|
| 4,947 |
Inventories |
| 2,661 |
|
| 2,869 |
Prepaid expenses and other receivables |
| 691 |
|
| 641 |
Total current assets |
| 9,886 |
|
| 10,558 |
Property, plant and equipment, net |
| 2,598 |
|
| 2,623 |
Product acquisition costs |
| 1,736 |
|
| 1,766 |
Restricted cash, long term |
| 54 |
|
| 54 |
License fee, net |
| 175 |
|
| 200 |
Debt issuance costs, net |
| 61 |
|
| 69 |
Other |
| 157 |
|
| 157 |
Total assets | $ | 14,667 |
| $ | 15,427 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable | $ | 1,339 |
| $ | 1,523 |
Accrued expenses |
| 2,004 |
|
| 2,915 |
Deferred income, current |
| 360 |
|
| 768 |
Capital lease obligation, current |
| 11 |
|
| 15 |
Total current liabilities |
| 3,714 |
|
| 5,221 |
|
|
|
|
|
|
Note payable, bank |
| 3,000 |
|
| 3,000 |
Other long term liabilities |
| 12 |
|
| 15 |
Total liabilities |
| 6,726 |
|
| 8,236 |
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
Common stock, $0.01 par value, 60,000,000 shares authorized; |
|
|
|
|
|
Additional paid-in capital |
| 52,121 |
|
| 51,541 |
Accumulated deficit |
| (44,670) |
|
| (44,837) |
Total stockholders’ equity |
| 7,941 |
|
| 7,191 |
Total liabilities and stockholders' equity | $ | 14,667 |
| $ | 15,427 |
*Derived from the audited December 31, 2013 financial statements
3
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the three months ended March 31, 2014 and 2013
(in thousands)
(Unaudited)
| 2014 |
| 2013 | ||
|
|
|
|
|
|
Cash flows from operating activities: |
|
|
|
|
|
Net income (loss) | $ | 167 |
| $ | (257) |
Non-cash expenses |
| 429 |
|
| 196 |
Changes in operating assets and liabilities |
| (533) |
|
| (1,533) |
|
|
|
|
|
|
Net cash provided by (used in) operating activities |
| 63 |
|
| (1,594) |
|
|
|
|
|
|
Net cash used in investing activities |
| (68) |
|
| (1,486) |
|
|
|
|
|
|
Net cash provided by financing activities |
| 318 |
|
| 1,190 |
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
| 313 |
|
| (1,890) |
Cash and cash equivalents at beginning of period |
| 2,101 |
|
| 2,536 |
Cash and cash equivalents at end of period | $ | 2,414 |
| $ | 646 |
4
About IGI Laboratories, Inc.
IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.
IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," “believe”, “target”, “estimated,” "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Actual results may differ materially from these expectations. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
5